Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 50Active not recruiting 32Completed 15Terminated 9Not yet recruiting 3Withdrawn 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 51Breast Neoplasms 40Colorectal Neoplasms 26Prostatic Neoplasms 22Lung Neoplasms 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 14Brain Neoplasms 11Hematologic Neoplasms 10Pancreatic Neoplasms 9Colonic Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Head and Neck Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Melanoma 7Liver Neoplasms 7Leukemia, Myeloid, Acute 7Disease 7Anxiety Disorders 7Myasthenia Gravis 6Multiple Myeloma 6Barrett Esophagus 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Lymphoma, Non-Hodgkin 5

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Leukemia, Myelomonocytic, Chronic × 1 year × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡